Cancer Treatment
Cancer Clinical Trials
Your access to cutting-edge cancer treatments.
As a leader in clinical oncology research, our Sharp Center for Research offers you the latest clinical trials that assist in discovery of new and improved treatments to help you overcome cancer. With a wide selection of open trials for almost every tumor site we give you more options for cancer research.
As a participant of a clinical trial, you are guided through the use of experimental drugs or treatments that have been recommended based on your type of cancer. Please visit the links below for additional detailed information about our clinical trials.
How clinical trials work
More people are living longer thanks to successful cancer treatments resulting from clinical trials. Before new treatments are introduced to patients, they are first studied in the laboratory.
Once preliminary research indicates the possible benefits of a new treatment, clinical trials go through three phases. Phase 1 tests for safety, Phase 2 tests for effectiveness, and Phase 3 tests for both safety and effectiveness in a larger group of patients.
Only after a new treatment passes all three clinical trial phases is it then cleared for general use. All approved cancer treatments available today began as clinical trials.
Why consider joining a clinical trial?
High-level patient care — Participants receive close monitoring and guidance by clinical trial coordinators and their oncologist.
Access to promising new treatments — Participants may receive a treatment that will be more effective than the standard treatment, and unavailable outside of a clinical trial.
Better treatments — Participants help expand researchers' knowledge and determine whether new treatments will improve outcomes for future patients with cancer.
Cost to participate
There may be some costs associated with participating in a trial. Most patients are responsible for copays and deductibles as they would be if they were receiving treatment outside of a clinical trial. The research team will discuss any possible costs with you prior to enrolling.
How to participate
Ask your doctor if any study at Sharp may be appropriate for you. Your doctor should explain the criteria for trial eligibility, including the stage of cancer being studied; how results will be evaluated; and the potential benefits and risks, such as side effects or other health impacts.
You will receive an informed consent form outlining the purpose of the clinical trial and the risks involved. If there is anything on the form that you do not understand, ask your doctor before signing.
During a clinical trial, you will be monitored and observed closely. If at any time you or your doctor believes the treatment is not in your best interest, you can leave the study.
Enroll in an active cancer clinical trial.
If you are interested in participating in a clinical trial, please consult with your physician or contact the Sharp Center for Research by calling 858-939-4030 or by sending us an email.
Brain
- SHCGBM-002, Evaluation of HER-2 Receptor Expression and HER-2/neu Gene Amplification in Glioblastoma Patients, Amtower Foundation
- A071701, Genomically-guided Treatment Trial in Brain Metastases (NCT03994796), Alliance for Clinical Trials in Oncology
- INCB 54828-209 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (NCT05267106), Incyte Corporation
- NAS-101 A Phase 1, Sequential Cohort, Open-Label, Dose-Escalation Study of the Safety and CNS Exposure of Pritumumab in Patients with Brain Cancer (NCT04396717), Nascent Biotech
- EF-32 (Trident): A Pivotal Randomized, Open-Label Study of Optune® (TTFIELDS, 200KHZ) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (NCT04471844)
Breast
- AFT-25, Comparison Of Operative To Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (NCT02926911), Alliance Foundation Trials, LLC
- D9673C00007, An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12) (NCT04739761), AstraZeneca
- D8534C00001, SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study (NCT04964934), AstraZeneca
- V2000701, A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib, Veru Inc.
Colon
- A021502, Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559), Alliance for Clinical Trials in Oncology
- 849-010, A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (NCT04793958), Mirati Therapeutics, Inc.
Lung
- EF-25, METIS: Pivotal, open-label, randomized study of radiosurgery with or without tumor treating fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC) (NCT02831959), NovoCure Ltd.
- D9103C00001, A phase III, randomized, placebo-controlled, double-blind, multicenter, international study of Durvalumab following stereotactic body radiation therapy (SBRT) for the treatment of patients with unresected stage I/II, lymph-node negative non-small cell lung cancer (PACIFIC-4/RTOG-3515) (NCT03833154), AstraZeneca
Lymphoma
- ME-401-003, A Multicenter, Open-Label, Single-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies (NCT03768505), MEI Pharma, Inc.
- INCMOR0208-301, A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma, (NCT04680052), Incyte Corporation
- MOR208C310, MorphoSys AG / “A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high- intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)”, (NCT04824092), MorphoSys AG
Melanoma
- S2000, A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases (NCT04511013), Southwest Oncology Group
Pancreatic
- 18-0402, A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy (NCT04068896), NGM Biopharmaceuticals, Inc.
Rare tumors
- S1609, DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (NCT02834013), National Cancer Institute
Renal
- A031704, PD-inhibitor (Nivolumab) and Ipilimumab followed by nivolumab vs VEGF TKI cabozantinib with nivolumab: A Phase III Trial in metastatic untreated Renal Cell Cancer (PDIGREE) (NCT03793166), National Cancer Institute
Solid tumor
- EAY131, Molecular Analysis for Therapy Choice (MATCH) (NCT02465060), National Cancer Institute
- 18-0402, A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy (NCT04068896), NGM Biopharmaceuticals, Inc.
- DF1001-001, A phase I/II, first-in-human, multipart, open-label, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of DF1001 in patients with locally advanced or metastatic solid tumors, and expansion in selected indications (NCT04143711), Dragonfly Therapeutics
- PREDAPT-2, A Multicenter Cancer Biospecimen Collection Study (NCT04510129), Cofactor Genomics, Inc.
- TEMPS-101, A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients with PALB2 Mutations (NCT05169437), Tempus Labs
We'll help find the doctor who's right for you.
View doctors specializing in oncology in San Diego.
All Categories
- Bariatric surgery
- Bariatric surgery seminars
- Bereavement
- Breast cancer
- Cancer
- Cancer support groups
- Caregiving
- Childbirth preparation
- Chronic disease management
- Community events
- Congestive heart failure
- Continuing education
- CPR and first aid
- Embarazo y parto
- En español
- Exercise
- Financial and health care planning
- Gentle exercise
- Health screenings
- Heart
- Integrative and complementary medicine
- Medicare
- Men's health
- Mental health
- Neonatal Resuscitation Program (NRP)
- Newborn and baby care
- Nutrition
- Online education programs
- Orthopedics
- Pain management
- Parenting and child development
- Pregnancy and childbirth
- Prenatal hospital tours
- Rehabilitation
- Robotic surgery
- Seniors and aging
- Sharp Chula Vista employees
- Sharp employee education
- Sharp employee online education
- Sharp Grossmont employees
- Sharp Metro employees
- Sharp Training Center
- Sharp-Rees Stealy employees
- Smoking cessation
- Stress management
- Stroke
- Volunteers
- Weight management
- Wellness
- Women's care
- View category descriptions
Contact Sharp HealthCare
Call 1-800-827-4277 or view our detailed phone directory.
If you are experiencing a medical emergency, call 911 or visit the nearest emergency room.
Please do not use this form to convey personal or medical information.
What's This?
These important numbers are located on your billing statement.

Find your SharpCare account number

What's GDPR?
The General Data Protection Regulation (GDPR) governs the processing of personal information gathered from individuals while they are in the European Union (EU) and parts of the EEA (European Economic Area, which currently includes Iceland, Lichtenstein and Norway).
We are sorry, but we are unable to process your price estimate if you live or are travelling within the EU or affiliated nations.
What's This?
Many surgery and procedure names sound similar. If possible, please provide the current procedure terminology (CPT) code, which can be found on the order from your doctor.
If you cannot provide the CPT code, please contact your doctor's office for the CPT or a detailed description of services.